Understand the source comparison
KPV Legal 2026 Status: Regulatory Comparison
| Peptide | FDA Approval Status | DEA Scheduling | Legal Procurement Path | Compounding Pharmacy Use | Enforcement Pattern | Bottom Line ||—|—|—|—|—|—|| KPV | Not approved; no active IND | Not scheduled | Legal for research; prohibited for therapeutic marketin
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- | Peptide | FDA Approval Status | DEA Scheduling | Legal Procurement Path | Compounding Pharmacy Use | Enforcement Pattern | Bottom Line ||—|—|—|—|—|—|| KPV | Not approved; no active IND | Not scheduled | Legal for research; prohibited for therapeutic marketing | Allowed under valid prescription in 503A/503B facilities | Enforcement targets suppliers making health claims, not researchers | Legal to purchase for research; illegal to market for human therapeutic use || Semaglutide (Wegovy, Ozempic) | FDA-approved NDA | Not scheduled | Prescription only; full regulatory approval | Compounded versions allowed during shortage under FDA policy | Enforcement against non-licensed prescribers and unapproved marketing | Fully legal for prescription use; compounded versions legal during shortage || BPC-157 | Not approved; no active IND | Not scheduled | Legal for research; prohibited for therapeutic marketing | Allowed under valid prescription in some states | Enforcement targets therapeutic clai